Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Occurrence of impaired fasting glucose in GH‐deficient adults receiving GH replacement compared with untreated subjects

Woodmansee, Whitney w. ; Hartman, Mark l. ; Lamberts, Steven w.j. ; Zagar, Anthony j. and Clemmons, David r. (2010) In Clinical Endocrinology 72(1). p.59-69
Abstract
Objective: The effects of GH replacement on glucose metabolism in GH-deficient (GHD) adults in clinical practice are not well defined. Therefore, we assessed GH treatment effects on fasting plasma glucose (FPG) and haemoglobin A1c (A1c) concentrations in GHD adults in a clinical setting.
Design: Post-hoc analysis of the observational Hypopituitary Control and Complications Study conducted at 157 US centres (1997-2002).
Patients: GH-deficient adults who were GH-naïve at study entry and had at least two FPG measurements.
Measurements: Effect of GH treatment on the frequency and time course of abnormal FPG (> or =5.6 mmol/l) development, FPG normalization, progression of increased FPG and abnormal follow-up A1c (>6%) values... (More)
Objective: The effects of GH replacement on glucose metabolism in GH-deficient (GHD) adults in clinical practice are not well defined. Therefore, we assessed GH treatment effects on fasting plasma glucose (FPG) and haemoglobin A1c (A1c) concentrations in GHD adults in a clinical setting.
Design: Post-hoc analysis of the observational Hypopituitary Control and Complications Study conducted at 157 US centres (1997-2002).
Patients: GH-deficient adults who were GH-naïve at study entry and had at least two FPG measurements.
Measurements: Effect of GH treatment on the frequency and time course of abnormal FPG (> or =5.6 mmol/l) development, FPG normalization, progression of increased FPG and abnormal follow-up A1c (>6%) values in GHD patients treated with GH (n = 403) or untreated (n = 169) at their physician's discretion.
Results: In subjects without pre-existing diabetes mellitus, development of an abnormal FPG tended to occur in a greater percentage of GH-treated than untreated subjects (35.3% versus 24.5, P = 0.06). Additionally, GH treatment was associated with a mild, transient increase in FPG and shorter time to development of an abnormal FPG in these subjects (P < 0.01). Most ( approximately 80%) abnormal FPG values were below 7 mmol/l and normalized in 69% of GH-treated subjects without diabetes. Treatment with GH had no effect on the rate of FPG normalization, progression of increased FPG or abnormal follow-up A1c values.
Conclusions: Initiation of GH replacement in GHD adults was associated with a mild increase in FPG that often normalized spontaneously. Nevertheless, clinicians should monitor FPG in patients receiving GH treatment.
(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
contributor
LU
author collaboration
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical Endocrinology
volume
72
issue
1
pages
59 - 69
publisher
Wiley-Blackwell
external identifiers
  • scopus:72249117360
ISSN
1365-2265
DOI
10.1111/j.1365-2265.2009.03612.x
language
English
LU publication?
no
id
b7312ab8-11df-45a2-8879-9f9dda7f5565
date added to LUP
2023-11-14 13:00:23
date last changed
2023-11-15 04:02:07
@article{b7312ab8-11df-45a2-8879-9f9dda7f5565,
  abstract     = {{Objective: The effects of GH replacement on glucose metabolism in GH-deficient (GHD) adults in clinical practice are not well defined. Therefore, we assessed GH treatment effects on fasting plasma glucose (FPG) and haemoglobin A1c (A1c) concentrations in GHD adults in a clinical setting.<br/>Design: Post-hoc analysis of the observational Hypopituitary Control and Complications Study conducted at 157 US centres (1997-2002).<br/>Patients: GH-deficient adults who were GH-naïve at study entry and had at least two FPG measurements.<br/>Measurements: Effect of GH treatment on the frequency and time course of abnormal FPG (&gt; or =5.6 mmol/l) development, FPG normalization, progression of increased FPG and abnormal follow-up A1c (&gt;6%) values in GHD patients treated with GH (n = 403) or untreated (n = 169) at their physician's discretion.<br/>Results: In subjects without pre-existing diabetes mellitus, development of an abnormal FPG tended to occur in a greater percentage of GH-treated than untreated subjects (35.3% versus 24.5, P = 0.06). Additionally, GH treatment was associated with a mild, transient increase in FPG and shorter time to development of an abnormal FPG in these subjects (P &lt; 0.01). Most ( approximately 80%) abnormal FPG values were below 7 mmol/l and normalized in 69% of GH-treated subjects without diabetes. Treatment with GH had no effect on the rate of FPG normalization, progression of increased FPG or abnormal follow-up A1c values.<br/>Conclusions: Initiation of GH replacement in GHD adults was associated with a mild increase in FPG that often normalized spontaneously. Nevertheless, clinicians should monitor FPG in patients receiving GH treatment.<br/>}},
  author       = {{Woodmansee, Whitney w. and Hartman, Mark l. and Lamberts, Steven w.j. and Zagar, Anthony j. and Clemmons, David r.}},
  issn         = {{1365-2265}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{1}},
  pages        = {{59--69}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Clinical Endocrinology}},
  title        = {{Occurrence of impaired fasting glucose in GH‐deficient adults receiving GH replacement compared with untreated subjects}},
  url          = {{http://dx.doi.org/10.1111/j.1365-2265.2009.03612.x}},
  doi          = {{10.1111/j.1365-2265.2009.03612.x}},
  volume       = {{72}},
  year         = {{2010}},
}